Product Name :
SW106065
Description:
SW106065 is an apoptosis inducer in malignant peripheral nerve sheath tumors (MPNST). SW106065 inhibits ATP consumption of sMPNST and other models of MPNST with an EC50 of 1 µM. SW106065 can be used for MPNST research.
CAS:
62289-81-0
Molecular Weight:
204.25
Formula:
C10H8N2OS
Chemical Name:
N-(pyridin-3-yl)thiophene-2-carboxamide
Smiles :
O=C(NC1=CN=CC=C1)C1=CC=CS1
InChiKey:
UPLHUDRMLWWFRE-UHFFFAOYSA-N
InChi :
InChI=1S/C10H8N2OS/c13-10(9-4-2-6-14-9)12-8-3-1-5-11-7-8/h1-7H,(H,12,13)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
SW106065 is an apoptosis inducer in malignant peripheral nerve sheath tumors (MPNST). SW106065 inhibits ATP consumption of sMPNST and other models of MPNST with an EC50 of 1 µM. SW106065 can be used for MPNST research.{{Trastuzumab deruxtecan} medchemexpress|{Trastuzumab deruxtecan} JAK/STAT Signaling|{Trastuzumab deruxtecan} Biological Activity|{Trastuzumab deruxtecan} In Vitro|{Trastuzumab deruxtecan} custom synthesis|{Trastuzumab deruxtecan} Autophagy} |Product information|CAS Number: 62289-81-0|Molecular Weight: 204.25|Formula: C10H8N2OS|Chemical Name: N-(pyridin-3-yl)thiophene-2-carboxamide|Smiles: O=C(NC1=CN=CC=C1)C1=CC=CS1|InChiKey: UPLHUDRMLWWFRE-UHFFFAOYSA-N|InChi: InChI=1S/C10H8N2OS/c13-10(9-4-2-6-14-9)12-8-3-1-5-11-7-8/h1-7H,(H,12,13)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 100 mg/mL (489.60 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|SW106065 (Compound 21, Cpd21) inhibits the human MPNST cell lines growth in a dose-dependent manner, and EC50 concentrations of 439 nM and 753.6 nM for S462 and SNF96.2 cells, respectively. SW106065 remains nontoxic to normally dividing Schwann cells or mouse embryonic fibroblasts.{{Vortioxetine} site|{Vortioxetine} Serotonin Transporter|{Vortioxetine} Biological Activity|{Vortioxetine} In Vivo|{Vortioxetine} manufacturer|{Vortioxetine} Autophagy} SW106065 (Cpd21; 0.PMID:23819239 25-5 µM; 24 hours; sMPNST cells) treatment shows a decreased percentage of cells in S phase, and a corresponding increased percentage in G1/G0 and G2/M. SW106065 (Cpd21; 0.25-5 µM; 24 hours; sMPNST cells) treatment decreases the levels of cyclin A2, cyclin B1, cyclin D1, cyclin E, cdk4, and cdk6. And increases levels of cdkn1a and cdkn2a mRNA were observed in a dose-dependent manner.SW106065 (Cpd21; 0.25-5 µM; 24 hours; sMPNST cells) treatment decreases the levels of Cyclin D1 protein. SW106065 (Cpd21) treatment significant increase in the percentage of apoptotic cells.|In Vivo:|SW106065 (Cpd21; 40 mg/kg; intraperitoneal injection; twice per day for 4 weeks) treatment can be delivered to mice in concentrations to sufficiently penetrate sMPNST tissue, and inhibit tumor development.|Products are for research use only. Not for human use.|
